LONDON (Reuters) – AstraZeneca’s unique boss mentioned the drugmaker faced a tough year, with sales expected to fall with a mid-to-high single digit percentage rate because patent expiries continued to erode company. Earnings usually decline “more than revenue” this year because running fees rise, Britain’s 2nd largest drugmaker mentioned about Thursday. The outlook was worse than the decline of about 3 % inside 2013 sales which analysts had been expecting, plus shares inside the group fell four.1 % by 0840 GMT. …
Earnings News Headlines – Yahoo! News
There are no comments yet. Why not be the first to speak your mind.